Department of Medicine Solna, Karolinska Institutet, Solnavägen 1, 171 76, Stockholm, Sweden.
Medical/Steno Aarhus Research Laboratory, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Cardiovasc Diabetol. 2022 Jul 8;21(1):129. doi: 10.1186/s12933-022-01562-0.
Mannose binding lectin (MBL) has been suggested to be associated with an impaired cardiovascular prognosis in dysglycaemic conditions, but results are still contrasting. Our aims are (i) to examine whether MBL levels differ between patients with an acute myocardial infarction (MI) and healthy controls and between subgroups with different glucose tolerance status, and (ii) to investigate the relation between MBL and future cardiovascular events.
MBL levels were assessed at discharge and after 3 months in 161 AMI patients without any previously known glucose perturbations and in 183 age- and gender-matched controls from the Glucose metabolism in patients with Acute Myocardial Infarction (GAMI) study. Participants were classified as having dysglycaemia, i.e. type 2 diabetes or impaired glucose tolerance, or not by an oral glucose tolerance test. The primary outcome was a composite of cardiovascular events comprising cardiovascular death, AMI, stroke or severe heart failure during 11 years of follow-up. Total and cardiovascular mortality served as secondary outcomes.
At hospital discharge patients had higher MBL levels (median 1246 μg/L) than three months later (median 575 μg/L; p < 0.01), the latter did not significantly differ from those in the controls (801 μg/L; p = 0.47). MBL levels were not affected by dysglycaemia either in patients or controls. Independent of glycaemic state, increasing MBL levels did not predict any of the studied outcomes in patients. In unadjusted analyses increasing MBL levels predicted cardiovascular events (hazard ratio HR: 1.67, 95% confidence interval CI 1.06-2.64) and total mortality (HR 1.53, 95% CI 1.12-2.10) in the control group. However, this did not remain in adjusted analyses.
Patients had higher MBL levels than controls during the hospital phase of AMI, supporting the assumption that elevated MBL reflects acute stress. MBL was not found to be independently associated with cardiovascular prognosis in patients with AMI regardless of glucose state.
甘露糖结合凝集素(MBL)被认为与糖代谢异常患者的心血管预后受损有关,但结果仍存在差异。我们的目的是:(i)检查急性心肌梗死(MI)患者与健康对照组之间以及不同葡萄糖耐量状态亚组之间的 MBL 水平是否存在差异,(ii)研究 MBL 与未来心血管事件的关系。
在无任何先前已知葡萄糖紊乱的 161 名急性心肌梗死患者和 Glucose metabolism in patients with Acute Myocardial Infarction(GAMI)研究中的 183 名年龄和性别匹配的对照组中,分别在出院时和 3 个月时评估 MBL 水平。通过口服葡萄糖耐量试验将参与者分为糖代谢异常(即 2 型糖尿病或糖耐量受损)或无异常。主要结局是 11 年随访期间的心血管事件复合结局,包括心血管死亡、心肌梗死、卒中和严重心力衰竭。总死亡率和心血管死亡率作为次要结局。
在出院时,患者的 MBL 水平(中位数 1246μg/L)高于 3 个月后的水平(中位数 575μg/L;p<0.01),后者与对照组(801μg/L;p=0.47)无显著差异。在患者和对照组中,MBL 水平不受糖代谢异常的影响。无论糖状态如何,MBL 水平的升高都不能预测患者的任何研究结局。在未调整的分析中,MBL 水平的升高预示着对照组中的心血管事件(危险比 HR:1.67,95%置信区间 CI 1.06-2.64)和总死亡率(HR 1.53,95% CI 1.12-2.10)。然而,在调整后的分析中,这一结果并不成立。
在急性心肌梗死的住院阶段,患者的 MBL 水平高于对照组,这支持了升高的 MBL 反映急性应激的假设。无论葡萄糖状态如何,MBL 都与急性心肌梗死患者的心血管预后无关。